Clinical trials: Cancer Stem Cells
Brain and Central Nervous System Tumors
Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00278278
- Testing
- cisplatin, etoposide, ifosfamide
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- German Society for Pediatric Oncology and Hematology GPOH gGmbH
Chronic Myelogenous Leukemia
Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML)
In this research study, the investigators are looking to see whether the combination of arsenic trioxide with a tyrosine kinase inhibitor is safe, and what effects it has on chronic myelogenous leukemia.
- Trial name
- NCT01397734
- Testing
- Arsenic trioxide
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Beth Israel Deaconess Medical Center
Hematologic Malignancy, Leukemia
A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives
This phase II clinical trial studies how well two donors stem cell transplant work in treating patients with high-risk hematologic malignancies.
- Conditions
- Hematologic Malignancy, Leukemia, Acute Lymphoblastic Leukemia, ALL
- Trial name
- NCT01532635
- Testing
- Total Body Irradiation (TBI), Donor Lymphocyte Infusion (DLI), Cyclophosphamide (CY)
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Plasma Cell Myeloma
Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization
This early phase I trial studies how well loratadine works in reducing granulocyte-colony stimulating factor (G-CSF) induced bone pain in patients with multiple myeloma who are undergoing stem cell mobilization.
- Trial name
- NCT04211259
- Testing
- Loratadine, Questionnaire Administration
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- Rutgers, The State University of New Jersey
Advanced Colorectal Cancer
Chemokine and Co-stimulatory Molecule-modified Mesenchymal Stem Cells for the Treatment of Advanced Colorectal Cancer
The aim of this study is to assess the safety and efficacy of human umbilical cord-derived allogenic mesenchymal stem cells (MSCs) engineered to express antitumor chemokine and co-stimulatory molecule.
- Trial name
- NCT06446050
- Testing
- MSC-L
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai East Hospital
Acute Myeloid Leukaemia, High-risk Myelodysplastic Syndrome
A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT
Treatment options for older adults with Acute Myeloid Leukaemia (AML) and Myelodysplasia (MDS) are limited. Although stem cell transplantation remains one of the most effective treatments it is associated with severe side effects…
- Trial name
- COSI (NCT04217278)
- Testing
- Vyxeos, Fludarabine, Busulphan
- Where
- 14 sites in United Kingdom
- Volunteers
- 333 people
- Sponsor
- University of Birmingham
Acute Myeloid Leukemia
Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant
AML is the most common acute leukemia in adults. Most patients can undergo allogeneic stem cell transplantation as a possible cure; however, many patients are not candidates for allogeneic transplant due to age, overall health…
- Trial name
- NCT02771197
- Testing
- Fludarabine, Melphalan, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Northside Hospital, Inc.
Atopic Dermatitis, Healthy
Cytokine Production Patterns in Patients With Systemic Mastocytosis Compared With Atopic Dermatitis and Healthy Individuals
Cytokine Production Patterns in Patients with Systemic Mastocytosis Compared with Atopic Dermatitis and Healthy Individuals Summary: This study will examine how mast cells (cells involved in allergic reactions) migrate and…
- Conditions
- Atopic Dermatitis, Healthy, Mastocytosis
- Trial name
- NCT00001760
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Chronic Ischemic Left Ventricular Dysfunction, Myocardial Infarction
The Transendocardial Autologous Cells (hMSC) or (hMSC) and (hCSC) in Ischemic Heart Failure Trial.
Before initiating the full randomized study, a Pilot Safety Phase will be performed. In this phase the composition of cells administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested.
- Trial name
- TAC-HFT-II (NCT02503280)
- Testing
- Autologous hMSCs, Autologous Human C-Kit CSCs II, Biosense Webster MyoStar NOGA Injection Catheter System
- Where
- United States
- Sponsor
- Joshua M Hare
Hodgkin Lymphoma
Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.
This study will assess RAD001 in patients with refractory or relapsed Hodgkin Lymphoma that has progressed after high-dose chemotherapy and Autologous Stem cell transplant and/or after gemcitabine- or vinorelbine- or…
- Trial name
- NCT01022996
- Testing
- Everolimus (RAD001)
- Where
- 16 sites in United States
- Volunteers
- 57 people
- Sponsor
- Novartis Pharmaceuticals
Blood Cancer, Blood and Marrow Transplant (BMT)
Stem Cell Transplant From Matched Unrelated or Partially Matched Related Donors
To evaluate the use of unrelated donors for hematopoietic cell transplantation in the treatment of hematologic and lymphoid malignancies.
- Trial name
- NCT00186225
- Testing
- ablative allogeneic hematopoietic cell transplantation
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Stanford University
Waldenstrom's Macroglobulinemia
Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia
The main goal of this clinical research study is to learn if Velcade ® (bortezomib) given with rituximab can help to control WM.
- Trial name
- NCT00492050
- Testing
- Bortezomib, Rituximab, Valacyclovir
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- M.D. Anderson Cancer Center
Hematological Malignancies
Study of a Reduced-toxicity "Submyeloablative" Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies
The goal of this prospective study is to assess the overall mortality (whether related to relapse/progression or toxicity - TRM-) at one year after allogeneic stem cell transplantation prepared by a so-called reduced-toxicity…
- Trial name
- ITT 08-01 (NCT00841724)
- Testing
- Fludarabine, Busulfan, Thymoglobuline
- Where
- 3 sites in France
- Volunteers
- 82 people
- Sponsor
- Nantes University Hospital
DIPG Brain Tumor, Diffuse Brainstem Glioma
Single Patient Compassionate Use / Expanded Access L-S-Gboxin (Lyophilized Form of S-Gboxin) for the Treatment of Diffuse Midline Glioma
F. 50y.o. 77kg, DS confirmed 18 Nov. 2022 Received treatment: 11 courses of TMZ (240mg) Radiotherapy 30 courses of 1.8Gr (total 54 Gr, TMZ 140 mg on RT). Bevacizumab intravenously -400 mg -0-14-28-42 (December-February 2023).
- Conditions
- DIPG Brain Tumor, Diffuse Brainstem Glioma, H3 K27M, H3 K28M
- Trial name
- TRIANGLE (NCT06439849)
- Testing
- S-Gboxin
- Sponsor
- Petrov, Andrey
Hematological Malignancy
Phase I of Infusion of Selected Donor NK Cells After Allogeneic Stem Cell Transplantation
The goal of our study will be to determine the clinical and biological safety of infusing immuno-selected NK (Natural Killer) CD3-/CD56+ cells, early after allogeneic transplantation with colony stimulating factor (G-CSF)…
- Trial name
- DLI-NK (NCT01853358)
- Testing
- NK Cell infusion
- Where
- France
- Volunteers
- 17 people
- Sponsor
- Institut Paoli-Calmettes
Chronic Myeloid Leukemia
Venetoclax After TKI to Target Persisting Stem Cells in CML
There is currently no available treatment, capable to increase the rate of sustained deep molecular remissions after TKI discontinuation in CML. Venetoclax could be such a drug.
- Trial name
- VARIANT (NCT05701215)
- Testing
- Venetoclax
- Where
- 2 sites in Germany
- Volunteers
- 10 people
- Sponsor
- Thomas Ernst, PD Dr. med.
Myeloma
TMC (Topotecan, Cyclophosphamide and Melphalan) for Multiple Myeloma
To determine the efficacy of high-dose topotecan, cyclophosphamide and melphalan in patients with Multiple Myeloma.
- Trial name
- NCT01039025
- Testing
- Topotecan, Cyclophosphamide, Melphalan
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma
Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate tumor cells and either kill them or deliver tumor-killing…
- Trial name
- NCT00020943
- Testing
- filgrastim, rituximab, carmustine
- Where
- 81 sites in United States, Puerto Rico
- Volunteers
- 79 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Multiple Myeloma
Evaluate Safety and Efficacy of High-dose Melphalan HCL for Injection in MM Patients With Auto-HSC Transplantation
The goal of this clinical trial is to learn if high-dose Melphalan HCl for Injection works to treat multiple myeloma. It will also learn about the safety of high dose Melphalan HCl for Injection.
- Trial name
- NCT06425276
- Testing
- Melphalan Hydrochloride for Injection
- Where
- China
- Volunteers
- 67 people
- Sponsor
- CASI Pharmaceuticals (China) Co., Ltd.
Refractory Plasma Cell Myeloma
Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant
This phase II trial studies how well giving bortezomib, lenalidomide, and dexamethasone together works in treating patients with multiple myeloma undergoing stem cell transplant.
- Trial name
- NCT02353468
- Testing
- Bortezomib, Lenalidomide, Dexamethasone
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Colorado, Denver
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.